Core Viewpoint - The ACCSI 2025 Science Instrument Investment and Financing Forum is set to gather over 70 investment institutions, focusing on cutting-edge technological innovation and industrial application, indicating a shift in the capital narrative within the scientific instrument industry [2][4]. Industry Insights - The Chinese scientific instrument industry is experiencing a "warm spring" in the capital market amidst global trade frictions, providing opportunities to explore technological investment trends and industry transformations [4]. - The forum aims to facilitate effective communication among various stakeholders in the scientific instrument sector, including government, industry, academia, research, application, capital, and media [15]. Investment Landscape - A total of 25 confirmed investment institutions have collectively invested over 20 billion in the scientific instrument sector over the past three years, with the National Science Capital (国科系) holding the highest share [9]. - The investment institutions can be categorized into five main groups: 1. "National Team" Technology Capital, focusing on critical areas like semiconductor equipment and precision instruments [9]. 2. Leading firms such as Peak Rui Capital and Cornerstone Capital, emphasizing technology barriers and import substitution [10]. 3. Industrial Capital, represented by major players like Haier Capital and Shanghai Haimai Chuangxin [10]. 4. Regional Industrial Capital, which is closely tied to local industry clusters and government guidance [10]. 5. Comprehensive Investment Groups, such as Beijing Qianhong Group, focusing on high-end equipment manufacturing [10]. Forum Agenda - The forum will feature various presentations and roadshows, including topics on automation micro-nano optical chip testing systems and AI-driven imaging instruments, showcasing innovations in the scientific instrument field [15]. - Notable speakers include researchers and executives from leading organizations, discussing the innovation and development paths of the scientific instrument industry under national strategic guidance [12][14]. Confirmed Participants - Over 50 investment institutions have confirmed their participation, with diverse investment focuses ranging from hard technology to advanced manufacturing and medical devices [11].

导读： 中国石化牵头启动石化行业智能工厂首批六项行业标准编制，计划2025年底前完成，将解决行业智能工厂定义、建设和实施路径等核心问题，推动全产业 链协同创新。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 4月2 2日，中国石油化工集团有限公司在北京主持召开石化行业智能工厂首批六项行业标准编制启动会。此次标准编制工作由石化盈科信息技 术有限责任公司担任牵头单位，联合中国石化、中国石油、中国海油三大能源央企，以及中国电子技术标准化研究院等1 8家科研机构、行业协 会与产业链企业共同参与，计划于2 0 2 5年1 2月底前完成标准报批程序。该举措标志着我国石化行业首次系统性构建智能工厂标准体系。 2 0 2 4年1月，工业和信息化部将石化行业智能工厂系列标准纳入第六批行业标准制修订计划。本次启动编制的六项核心标准涵盖《石化行业智 能工厂 参考架构》《石化行业智能工厂 信息模型》及《石化行业智能工厂运行管理系统》四大类标准（注：原文提及四项系列标准，实际为 运 行 管 理 系 统 下 细 分 的 设 备 、 生 产 、 安 全 、 能 源 等 ...

中国科学技术大学2 0 2 5年4 ~ 1 0月仪器设备采购意向汇总表 | 采购 | | 预算 | 采购 | | --- | --- | --- | --- | | | 需求概况 | | | | 项目 | | 万元 | 时间 | | | 为了实现高空间分辨率和高精度的同位素组成分析，团队 | | | | 飞秒激光 | 拟于2025年内采购一台套飞秒激光剥蚀系统，联用目前已 | 240 | 2025年 7月 | | 剥蚀系统 | 有的碰撞反应池电感耦合等离子体多接收质谱仪，实现原 | | | | | 位和快速的同位素组成测量。 | | | | | 1、光片厚度1～4μm可调；2、四侧照明，水平上样，倒置 | | | | 激光片层 | 成像，样本激发更均匀；3、支持拍摄样品体积不小于 | | | | 扫描显微 | 20×63×15mm；4、速度快，小鼠全脑16×12×8mm样本， | 500 | 2025年 | | | 4×镜头，从上样、拍摄、拼接；5、四通道激光器，405、 | | 7月 | | 镜 | 488、561、647nm；6、TB级数据拼接、渲染、解卷积、 | | | | | 制作视频，原始数据格式为 ...

Core Viewpoint - Haier Biomedical's Q1 revenue reached 688.99 million, a year-on-year increase of 0.30%, indicating a return to normal business development despite challenges in the market [2][3]. Revenue Summary - Total revenue for Q1 2025 was 688.99 million, compared to 686.91 million in the same period last year, reflecting a growth of 0.30% [3]. - Net profit attributable to shareholders decreased by 19.88% to 110.26 million, while the net profit after deducting non-recurring gains and losses fell by 25.38% to 99.17 million [3]. - Operating cash flow decreased significantly by 51.79% to 37.22 million [3]. - Basic and diluted earnings per share both dropped by 20.45% to 0.35 yuan [3]. Business Segment Performance - The Life Sciences segment generated revenue of 354 million, up 1.06% year-on-year and 53.28% quarter-on-quarter [3]. - The Medical Innovation segment reported revenue of 332 million, down 0.61% year-on-year but up 24.26% quarter-on-quarter [3]. Growth Drivers 1. Non-storage new industries maintained high growth, with revenue share at 44%, increasing by 13.92% year-on-year and 27.35% quarter-on-quarter, driven by growth in plasma consumables, medication automation, laboratory consumables, and instruments [4]. 2. Domestic scenario solutions continued to expand, with domestic market revenue at 482 million, down 3.35% year-on-year but up 54.98% quarter-on-quarter, enhancing brand strength and competitiveness [4]. 3. The overseas market showed signs of recovery with revenue of 204 million, a year-on-year increase of 9.88% and a quarter-on-quarter increase of 8.99%, reversing the decline seen in 2024 [4]. Future Industry Layout - Haier Biomedical is actively expanding into future industries such as CGT and blood management, launching an intelligent fully automated cell culture workstation and enhancing blood supply efficiency through AI and smart blood management systems [5].

Core Viewpoint - Beijing University of Chinese Medicine has announced multiple government procurement intentions for laboratory equipment, with a total budget of 116 million yuan [2][3]. Procurement Projects Summary - **Project for the Construction of Experimental and Practical Platforms for the School of Traditional Chinese Medicine**: Aimed at enhancing the practical teaching base, the project includes the purchase of 22 pieces of equipment and 10 chiral chromatography columns, with a budget of 1.5 million yuan, scheduled for April 2025 [4]. - **Project for the Improvement of Teaching Conditions for the School of Traditional Chinese Medicine**: This project addresses urgent needs for teaching operations and includes 32 items for digital imaging of pathological specimens, among other equipment, with a budget of 1.47 million yuan, also set for April 2025 [4]. - **High-Fidelity Human Engineering Platform Procurement**: This project involves purchasing small equipment to support a national-level platform, with a budget of 4.95 million yuan, planned for April 2025 [4]. - **Equipment Procurement for the Innovation Service Platform for Traditional Chinese Medicine Constitution and Chronic Disease Prevention**: This project focuses on essential equipment for life sciences, including PCR machines and various types of refrigerators, with a budget of 4.95 million yuan, scheduled for April 2025 [5]. - **Basic and Pharmaceutical Biological Evaluation Teaching Platform Construction Project**: This project aims to upgrade the teaching platform and includes 83 pieces of equipment, with a budget of 4.95 million yuan, planned for April 2025 [5]. - **Research and Pilot Testing Platform for Innovative Chinese Medicine**: This project will acquire a range of research equipment for the development of innovative Chinese medicine, including high-performance liquid chromatography systems and various analytical instruments, with a budget of 4.95 million yuan, scheduled for April 2025 [5].

Core Viewpoint - Recently, Tongji University announced multiple government procurement intentions, with a total budget of 127 million yuan for 16 items of instrument and equipment procurement [2]. Group 1: Project Overview - The project titled "Central Special Lottery Public Welfare Fund Support for Rare Disease Diagnosis and Treatment Capability Improvement Project (Phase VI)" has a budget of 480 million yuan [4][6]. - The procurement includes various genetic testing services, with specific budget allocations for different testing types [6]. Group 2: Procurement Details - The procurement documents can be obtained from April 30, 2025, to May 12, 2025, with a document price of 400 yuan [9][10]. - The deadline for submitting bids is May 23, 2025, at 09:00 AM (Beijing time) [10]. Group 3: Eligibility Requirements - Bidders must possess a valid medical institution practice license and cover the diagnostic subjects of "medical testing" and "clinical cell molecular genetics" [8]. - Suppliers listed as untrustworthy on the "Credit China" website are prohibited from participating in this project [13].

Core Viewpoint - The 18th China Scientific Instrument Development Annual Conference (ACCSI 2025) will be held from May 11-13, 2025, in Shanghai, focusing on the theme "Digital Intelligence Driven, New Quality Leading" [1][2][9]. Group 1: Event Overview - The conference aims to promote the healthy and rapid development of the Chinese scientific instrument industry by establishing an effective communication platform among government, industry, academia, research, application, investment, and media [2][9]. - ACCSI has been recognized as a high-level industry summit in the scientific instrument sector, having successfully held 17 sessions with attendance exceeding 1,500 participants per session, earning the title of the "Davos Forum" of the scientific instrument industry [3]. Group 2: Keynote Speaker - Academician Yu Dapeng from the Chinese Academy of Sciences has confirmed his attendance and will deliver a keynote speech emphasizing the need for self-reliance in quantum technology and the leading role of scientific instruments [4]. - Yu Dapeng is a prominent expert in quantum material control and quantum computing, with significant contributions to the field, particularly in the study of low-dimensional quantum materials [6]. Group 3: Conference Details - The conference will feature the "3i Award" ceremony, highlighting outstanding contributions in the scientific instrument field [1]. - The event will present the latest industry development policies, market demand information, and technological advancements from the past year to the attendees [3].

Core Viewpoint - BGI Genomics achieved a main business revenue of 2.957 billion yuan in 2024, with the sequencing instrument business contributing 2.348 billion yuan, reflecting a strategic focus on product innovation and market leadership in the domestic sequencing instrument sector [4][10]. Revenue Breakdown - The revenue from the gene sequencing instrument business reached 2.348 billion yuan, a year-on-year increase of 2.47%. The revenue from instrument equipment was 960 million yuan, up 6.92%, while reagent consumables generated 1.373 billion yuan, growing by 1.43% [4]. - The laboratory automation business generated 209 million yuan, showing a significant growth of 36.69% compared to 2023, excluding impacts from public health events [4]. - New business segments contributed 400 million yuan, with a year-on-year growth of 57.05%, also excluding public health event impacts [4]. Product Innovation - BGI Genomics launched a series of new sequencing instruments and reagents, establishing a comprehensive SEQ ALL matrix. The company is the first globally to have large-scale commercial production of both short-read and long-read sequencing products [5][6]. - New products include the StandardMPS 2.0 sequencing reagent, which enhances high-throughput sequencing quality to Q40 accuracy, and the DNBSEQ-E25 Flash sequencing instrument, which significantly accelerates sequencing speed while reducing error rates [6]. AI Integration - The company implemented an intelligent transformation in its laboratory automation business by integrating AI technology, creating a standardized library of functional modules for life science tools, enhancing operational efficiency and decision-making processes [7]. Multi-Omics Tools Development - BGI Genomics is advancing multi-omics tools to support high-throughput, low-cost omics data production, addressing key scientific questions in life sciences. Significant progress has been made in cell genomics, spatial genomics, and imaging [8]. - In cell genomics, the company released new preservation solutions and upgraded single-cell library preparation kits, becoming one of the few companies globally to offer a comprehensive range of single-cell applications [8]. Market Performance - In the domestic market, the revenue from gene sequencing instruments reached 1.607 billion yuan, a year-on-year increase of 11.37%, capturing a 39% market share in the upstream revenue of the domestic gene sequencing industry [10]. - The company installed over 1,000 new sequencing instruments in the domestic market, representing a 63.8% share of new installations in the domestic gene sequencing industry [10]. - In overseas markets, the revenue from gene sequencing instruments was 741 million yuan, a decline of 12.66%. The company faced challenges in the Asia-Pacific and Europe-Africa regions due to project delays and increased competition, while the Americas region saw an 8.28% revenue increase [11].

Core Viewpoint - The 18th China Scientific Instrument Development Annual Conference (ACCSI 2025) will be held from May 11 to 13, 2025, in Shanghai, focusing on the theme "Digital Intelligence Drives New Quality Leadership" [1][2]. Group 1: Conference Overview - ACCSI is positioned as a high-level industry summit for the scientific instrument sector, having successfully held 17 sessions with attendance exceeding 1,500 participants, earning the title of the "Davos Forum" for the scientific instrument industry [2]. - The conference aims to summarize the latest developments in the Chinese scientific instrument industry over the past year, presenting new industry development policies, market demand information, and technological advancements to attendees [2]. - Key industry figures, including government leaders, experts, CEOs, and investment institution heads, will provide strategic decision-making references through various formats such as reports, dialogues, and discussions [2]. Group 2: Event Schedule - The main conference will take place on May 12, 2025, from 09:00 to 11:20 at the Fuyue Hall 1+2+3 [6]. - The 6th Scientific Instrument CMO Summit Forum is scheduled for May 11, 2025, from 13:30 to 17:30 at Fuyue Hall 3 [2]. - Various specialized forums and roadshows will be held throughout the conference, focusing on topics such as high-end scientific instruments, artificial intelligence integration, and investment opportunities in the scientific instrument sector [19][20][25]. Group 3: Key Topics and Discussions - The conference will feature discussions on the development and application of hyperspectral and imaging technologies, quantum technology, and the strategic layout of companies like Shimadzu in the context of Chinese opportunities [7]. - A series of roadshows will showcase innovative projects, including automated micro-nano optical chip testing systems and advanced imaging platforms [15][19]. - The integration of artificial intelligence in scientific instruments will be a significant focus, with forums dedicated to exploring AI's role in driving innovation and transformation within the industry [24][25]. Group 4: Networking and Collaboration - The conference will facilitate networking opportunities among industry professionals, fostering collaboration between academia, industry, and government to enhance the scientific instrument ecosystem [2][19]. - The event will also include award ceremonies recognizing high-potential companies in the scientific instrument sector for the year 2024 [16]. Group 5: Future Directions - The conference aims to address the future trends and investment opportunities in high-end scientific instruments, emphasizing the importance of innovation and market adaptability [16][19]. - Discussions will also cover the digital transformation of the scientific instrument after-market services, focusing on proactive maintenance and user demand responsiveness [60].